Literature DB >> 10768834

Decreased expression of corticotropin-releasing factor-binding protein mRNA in ACTH-secreting pituitary adenomas.

K D Dieterich1, H Lehnert.   

Abstract

This study was designed to analyze the sequence and the expression of CRF-BP mRNA in ACTH-secreting pituitary adenomas. Direct sequencing analysis revealed no apparent mutations in the CRF-BP mRNA. Thus, we conclude that mutations in the coding region of the CRF-BP gene are not involved in the pathogenesis of Cushing's disease. However, using a semiquantitative PCR approach coamplifying the house-keeping gene GAPDH we detected a reduced expression of CRF-BP mRNA in ACTH-secreting pituitary adenomas when compared with normal pituitaries. We suggest that the decreased CRF-BP gene expression in ACTH-secreting pituitary adenomas is most likely an effect due to high cortisol levels in Cushing patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10768834     DOI: 10.1055/s-0032-1329217

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  3 in total

1.  Differential expression of toll-like receptor 3 and 5 in ileal pouch mucosa of ulcerative colitis patients.

Authors:  Gundi Heuschen; Christine Leowardi; Ulf Hinz; Frank Autschbach; Andreas Stallmach; Christian Herfarth; Udo A Heuschen
Journal:  Int J Colorectal Dis       Date:  2006-06-13       Impact factor: 2.571

Review 2.  The corticotropin releasing factor system in cancer: expression and pathophysiological implications.

Authors:  Athina Kaprara; Kalliopi Pazaitou-Panayiotou; Alexandros Kortsaris; Ekaterini Chatzaki
Journal:  Cell Mol Life Sci       Date:  2010-02-09       Impact factor: 9.261

3.  Reduced mRNA expression level of corticotropin-releasing hormone-binding protein is associated with aggressive human kidney cancer.

Authors:  Hossein Tezval; Faranaz Atschekzei; Inga Peters; Sandra Waalkes; Jörg Hennenlotter; Arnulf Stenzl; Jan U Becker; Axel S Merseburger; Markus A Kuczyk; Jürgen Serth
Journal:  BMC Cancer       Date:  2013-04-22       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.